TABLE 4.
Response to sunitinib treatment in CAM assaysa
| RCC cell line | Treatment | Tumor engraftment rate (%) (no. of samples with tumors/total no. of samples) | Su/Ve | P value |
|---|---|---|---|---|
| TG206 | Vehicle (n = 16) | 68.8 (11/16) | 0.40 | 0.037 |
| Sunitinib (n = 18) | 27.8 (5/18) | |||
| TG158 | Vehicle (n = 22) | 59.1 (13/22) | 0.47 | 0.042 |
| Sunitinib (n = 25) | 28.0 (7/25) | |||
| TG185 | Vehicle (n = 17) | 64.7 (11/17) | 0.39 | 0.022 |
| Sunitinib (n = 20) | 25.0 (5/20) | |||
| TG127 | Vehicle (n = 43) | 60.4 (26/43) | 0.89 | 0.628 |
| Sunitinib (n = 28) | 53.6 (15/28) | |||
| PF22 | Vehicle (n = 37) | 21.6 (8/37) | 1.12 | 1.000 |
| Sunitinib (n = 29) | 24.1 (7/29) | |||
| T258 | Vehicle (n = 27) | 63.0 (17/27) | 1.04 | 1.000 |
| Sunitinib (n = 23) | 65.2 (15/23) | |||
| TG121 | Vehicle (n = 31) | 64.5 (20/31) | 0.81 | 0.405 |
| Sunitinib (n = 21) | 52.4 (11/21) |
a
List of cell lines evaluated for sunitinib sensitivity in CAM assays. Cells are sorted based on sunitinib sensitivity (see Table 3). Sunitinib-resistant cell lines (as determined based on coculture assays) are indicated with boldface characters.